2
项与 Interferon alfa-2b(Nautilus Biotech SA) 相关的临床试验A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, Pharmacokinetic/Pharmacodynamic, and Preliminary Efficacy Study of Subcutaneous Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C
The primary objective of this study is to evaluate the safety and tolerability of ascending doses of Hanferon™ in combination with ribavirin (RBV). The secondary objective of this study is to define the PK and PD of ascending doses of Hanferon™ in combination with RBV. The exploratory objective of this study is to make a preliminary assessment of Hanferon™ efficacy in combination with RBV.
Mono-centre, open-label study to investigate the multi-dose pharmacokinetics, efficacy and safety of Interferon alpha-2b Cream in women with a history of cytological diagnosed Pap IIID, with a confirmed histological diagnosis of CIN I or II, and of confirmed HPV+ status - Interferon alpha-2b kinetics in Pap IIID women
100 项与 Interferon alfa-2b(Nautilus Biotech SA) 相关的临床结果
100 项与 Interferon alfa-2b(Nautilus Biotech SA) 相关的转化医学
100 项与 Interferon alfa-2b(Nautilus Biotech SA) 相关的专利(医药)
100 项与 Interferon alfa-2b(Nautilus Biotech SA) 相关的药物交易